MedTrace Logo

Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia

NCT04577040 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2020-10-06

No results posted yet for this study

Summary

To study Safety and efficacy of Tadalafil vs. Tadalafil with Sildosin in the management of moderately and severely symptomatic patients of prostatic hyperplasia

Conditions

  • Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia

Interventions

DRUG

Tadalafil 5mg

Drugs

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Eligibility

Min Age
45 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-10-01
Completion
2022-10-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577040 on ClinicalTrials.gov